Claims for Patent: 7,115,557

Summary for Patent: 7,115,557

Title:	Use of certain drugs for treating nerve root injury
Abstract:	The present invention relates to a method and a pharmaceutical composition for treatment of nerve disorders comprising administration of a therapeutically effective dosage of at least two substances selected from the group consisting of TNF inhibitors, IL-1 inhibitors, IL-6 inhibitors, IL-8 inhibitors, FAS inhibitors, FAS ligand inhibitors, and IFN-gamma inhibitors. Preferably, at least one of the substances is a TNF inhibitor.
Inventor(s):	Olmarker; Kjell (Molndal, SE)
Assignee:	Sciaticon AB (Molndal, SE)
Application Number:	10/225,237
Patent Claims:	1. A method for treatment of a nerve disorder selected from the group consisting of nerve root injury, sciatica, low back pain, whiplash associated disorder, nucleus pulposus-induced nerve injury, spinal cord compression, cervical rhizopathy, and a nerve disorder caused by a disk herniation in a subject comprising administering to said subject a therapeutically effective dosage of a first TNF inhibitor in combination with a second TNF inhibitor. 2. The method of claim 1, wherein said first TNF inhibitor is a specific TNF inhibitor and said second TNF inhibitor is a non-specific TNF inhibitor. 3. The method of claim 2, wherein said specific TNF inhibitor is infliximab, CDP-571 (Humicade.TM.), D2E7, or CDP-870. 4. The method of claim 2, wherein said specific TNF inhibitor is a soluble cytokine TNF receptor. 5. The method of claim 4, wherein said soluble cytokine TNF receptor is etanercept. 6. The method of claim 2, wherein said non-specific TNF inhibitor is a TNF inhibitor in the form of a binuclear DNA threading transition metal complex with anti-cancer effect. 7. The method of claim 2, wherein said non-specific TNF inhibitor is a TNF inhibitor in the form of a lactoferrin derivable peptide. 8. The method of claim 2, wherein said non-specific TNF inhibitor is an MMP inhibitor. 9. The method of claim 8, wherein said MMP inhibitor is doxycycline. 10. The method of claim 2, wherein said non-specific TNF inhibitor is a p38 kinase inhibitor. 11. The method of claim 2, wherein said non-specific TNF inhibitor is TTP. 12. The method of claim 2, wherein the subject is a vertebrate. 13. The method of claim 12, wherein the vertebrate is a mammal. 14. The method of claim 13, wherein the mammal is a human. 15. The method of claim 2, wherein said inhibitors are administered systemically or locally. 16. The method of claim 2, wherein said inhibitors are administered parenterally. 17. The method of claim 2, wherein said inhibitors are administered intramuscularly, intravenously, subcutaneously, orally, or rectally. 18. The method of claim 17, wherein said inhibitors are administered intravenously by injection or infusion. 19. The method of claim 18, wherein said specific TNF inhibitor is administered orally at a dosage of about 20 mg to about 1,500 mg. 20. The method of claim 2, wherein said specific TNF inhibitor is D2E7 and is administered in a dosage of about 0.1 mg/kg to about 50 mg/kg body weight of said subject. 21. The method of claim 2, wherein said specific TNF inhibitor is CDP-870 and is administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said subject. 22. A method for treatment of a nerve disorder selected from the group consisting of nerve root injury, sciatica, low back pain, whiplash associated disorder, nucleus pulposus-induced nerve injury, spinal cord compression, cervical rhizopathy, and a nerve disorder caused by a disk herniation in a subject comprising administering to said subject a therapeutically effective dosage of a TNF inhibitor in combination with a IL-1 inhibitor. 23. The method of claim 22, wherein said TNF inhibitor is infliximab, CDP-571 (Humicade.TM.), D2E7, or CDP-870. 24. The method of claim 22, wherein said TNF inhibitor is a soluble cytokine TNF receptor. 25. The method of claim 22, wherein said soluble cytokine TNF receptor is etanercept. 26. The method of claim 22, wherein said TNF inhibitor is a binuclear DNA threading transition metal complex with anti-cancer effect. 27. The method of claim 22, wherein said TNF inhibitor is a lactoferrin derivable peptide. 28. The method of claim 22, wherein said TNF inhibitor is an MMP inhibitor. 29. The method of claim 28, wherein said MMP inhibitor is doxycycline. 30. The method of claim 22, wherein said TNF inhibitor is a p38 kinase inhibitor. 31. The method of claim 22, wherein said TNF inhibitor is TTP. 32. The method of claim 22, wherein said IL-1 inhibitor is anakinra. 33. The method of claim 22, wherein the subject is a vertebrate. 34. The method of claim 33, wherein the vertebrate is a mammal. 35. The method of claim 34, wherein the mammal is a human. 36. The method of claim 22, wherein said inhibitors are administered systemically or locally. 37. The method of claim 22, wherein said inhibitors are administered parenterally. 38. The method of claim 22, wherein said inhibitors are administered intramuscularly, intravenously, subcutaneously, orally, or rectally. 39. The method of claim 38, wherein said inhibitors are administered intravenously by injection or infusion. 40. The method of claim 39, wherein said TNF inhibitor is administered orally at a dosage of about 20 mg to about 1,500 mg. 41. The method of claim 22, wherein said TNF inhibitor is D2E7 and is administered in a dosage of about 0.1 mg/kg to about 50 mg/kg body weight of said subject. 42. The method of claim 22, wherein said TNF inhibitor is CDP-870 and is administered in a dosage of about 1 mg/kg to about 50 mg/kg body weight of said subject.

Details for Patent 7,115,557

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2018-09-25
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2018-09-25
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2018-09-25
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2018-09-25